$MASI
MASIMO CORP Stock $masi

$masi Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000093755619000179 Filed on October 30, 2019

Income Statement

Concept	2019 Q3	2018 Q4	2018 Q3
Revenue	$229.0M	$223.1M	$210.6M
YoY Change	8.75%	7.31%	8.91%
Cost Of Revenue	$72.74M	$74.80M	$69.83M
YoY Change	4.17%	7.94%	0.77%
Gross Profit	$156.3M	$148.3M	$140.8M
YoY Change	11.02%	6.98%	13.45%
Gross Profit Margin	68.24%	66.48%	66.84%
Selling, General & Admin	$80.35M	$74.20M	$71.54M
YoY Change	12.33%	-4.63%	8.88%
% of Gross Profit	51.42%	50.02%	50.82%
Research & Development	$24.28M	$19.80M	$20.58M
YoY Change	18.02%	22.98%	34.48%
% of Gross Profit	15.54%	13.35%	14.62%
Depreciation & Amortization	$4.800M	$5.100M	$4.000M
YoY Change	20.0%	-10.53%	5.26%
% of Gross Profit	3.07%	3.44%	2.84%
Operating Expenses	$104.6M	$94.00M	$92.11M
YoY Change	13.6%	0.11%	13.71%
Operating Profit	$51.63M	$53.91M	$48.64M
YoY Change	6.15%	20.52%	12.96%
Interest Expense	$82.00K		$7.000K
YoY Change	1071.43%
% of Operating Profit	0.16%		0.01%
Other Income/Expense, Net	$2.723M	$1.700M	$1.028M
YoY Change	164.88%	142.86%	258.19%
Pretax Income	$54.36M	$55.60M	$49.67M
YoY Change	9.43%	22.47%	14.58%
Income Tax	$5.270M	$7.700M	-$7.457M
% Of Pretax Income	9.7%	13.85%	-15.01%
Net Earnings	$49.09M	$46.93M	$57.13M
YoY Change	-14.08%	-706.77%	59.33%
Net Earnings / Revenue	21.43%	21.03%	27.13%
Basic Earnings Per Share	$0.92	$0.88	$1.09
Diluted Earnings Per Share	$0.86	$0.83	$1.02
COMMON SHARES
Basic Shares Outstanding	53.54M shares	53.17M shares	52.43M shares
Diluted Shares Outstanding	57.26M shares		56.24M shares

Balance Sheet

Concept	2019 Q3	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$633.4M	$552.5M	$493.5M
YoY Change	28.35%	75.23%	48.91%
Cash & Equivalents	$513.4M	$552.5M	$493.5M
Short-Term Investments	$120.0M	$0.00
Other Short-Term Assets	$60.77M	$32.43M	$48.28M
YoY Change	25.86%	-3.5%	3.07%
Inventory	$109.7M	$94.73M	$92.95M
Prepaid Expenses	$10.05M	$10.58M	$10.86M
Receivables	$130.4M	$109.6M	$101.0M
Other Receivables	$29.90M	$10.30M	$18.20M
Total Short-Term Assets	$934.2M	$789.3M	$735.7M
YoY Change	26.98%	41.02%	34.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$209.5M	$166.0M	$164.6M
YoY Change	27.25%	1.14%	0.02%
Goodwill	$22.00M	$23.30M	$23.45M
YoY Change	-6.21%	13.0%	13.44%
Intangibles	$27.43M	$27.92M	$28.46M
YoY Change	-3.62%	2.95%	3.54%
Long-Term Investments	$6.287M	$1.200M
YoY Change		-2.76%
Other Assets	$29.38M	$4.232M	$3.859M
YoY Change	661.29%	-9.34%	-66.01%
Total Long-Term Assets	$380.0M	$365.5M	$360.1M
YoY Change	5.52%	5.73%	0.14%
TOTAL ASSETS
Total Short-Term Assets	$934.2M	$789.3M	$735.7M
Total Long-Term Assets	$380.0M	$365.5M	$360.1M
Total Assets	$1.314B	$1.155B	$1.096B
YoY Change	19.93%	27.54%	20.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.77M	$40.39M	$38.94M
YoY Change	4.7%	19.56%	-3.26%
Accrued Expenses	$5.387M	$5.038M	$4.727M
YoY Change	13.96%	72.3%	-88.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$150.0M	$146.6M	$143.6M
YoY Change	4.44%	13.04%	-16.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.204M	$39.20M	$87.00K
YoY Change	2433.33%	-24.27%	-70.21%
Total Long-Term Liabilities	$2.204M	$39.20M	$87.00K
YoY Change	2433.33%	-24.27%	-70.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$150.0M	$146.6M	$143.6M
Total Long-Term Liabilities	$2.204M	$39.20M	$87.00K
Total Liabilities	$205.9M	$185.8M	$183.5M
YoY Change	12.21%	2.39%	-2.82%
SHAREHOLDERS EQUITY
Retained Earnings	$1.048B	$931.1M	$884.1M
YoY Change	18.49%	26.17%	22.72%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$517.0M	$489.0M	$489.0M
YoY Change	5.71%	3.49%	8.78%
Treasury Stock Shares	15.46M shares	15.26M shares	15.26M shares
Shareholders Equity	$1.108B	$969.1M	$912.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.314B	$1.155B	$1.096B
YoY Change	19.93%	27.54%	20.95%

Cashflow Statement

Concept	2019 Q3	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$49.09M	$46.93M	$57.13M
YoY Change	-14.08%	-706.77%	59.33%
Depreciation, Depletion And Amortization	$4.800M	$5.100M	$4.000M
YoY Change	20.0%	-10.53%	5.26%
Cash From Operating Activities	$50.60M	$63.20M	$48.40M
YoY Change	4.55%	29.77%	-265.75%
INVESTING ACTIVITIES
Capital Expenditures	-$9.700M	-$5.700M	-$3.900M
YoY Change	148.72%	-14.93%	-20.41%
Acquisitions
YoY Change
Other Investing Activities	$54.80M	$0.00	-$3.500M
YoY Change	-1665.71%		218.18%
Cash From Investing Activities	$45.10M	-$5.600M	-$7.500M
YoY Change	-701.33%	-16.42%	53.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.800M	2.100M	22.60M
YoY Change	-56.64%	-112.28%	8.13%
NET CHANGE
Cash From Operating Activities	50.60M	63.20M	48.40M
Cash From Investing Activities	45.10M	-5.600M	-7.500M
Cash From Financing Activities	9.800M	2.100M	22.60M
Net Change In Cash	105.5M	59.70M	63.50M
YoY Change	66.14%	139.76%	-581.06%
FREE CASH FLOW
Cash From Operating Activities	$50.60M	$63.20M	$48.40M
Capital Expenditures	-$9.700M	-$5.700M	-$3.900M
Free Cash Flow	$60.30M	$68.90M	$52.30M
YoY Change	15.3%	24.37%	-315.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-28
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0000937556
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1535000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1946000	USD
CY2018Q3	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	500000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53085000	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53611000	shares
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.320
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.320
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.293
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.300
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.268
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92618
CY2018Q4	us-gaap	Inventory Net InventoryNet	94732000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	60769000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	29227000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	934216000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.268
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.287
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.283
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.026
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.027
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.023
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	15255000	shares
CY2019Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	15463000	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-28
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33642
	dei	Entity Registrant Name EntityRegistrantName	MASIMO CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0368882
	dei	Entity Address Address Line1 EntityAddressAddressLine1	52 Discovery
	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
	dei	City Area Code CityAreaCode	(949)
	dei	Local Phone Number LocalPhoneNumber	297-7000
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	MASI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53611086	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	513360000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	552490000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	120000000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	109689000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	786078000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130398000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	109629000	USD
CY2019Q3	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	47442000	USD
CY2018Q4	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	0	USD
CY2019Q3	us-gaap	Deferred Costs DeferredCosts	13820000	USD
CY2018Q4	us-gaap	Deferred Costs DeferredCosts	126105000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	209458000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165972000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27432000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27924000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	21997000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	23297000	USD
CY2019Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	30470000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	21210000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29378000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4232000	USD
CY2019Q3	us-gaap	Assets Assets	1314213000	USD
CY2018Q4	us-gaap	Assets Assets	1154818000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	40771000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40388000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	48238000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49486000	USD
CY2019Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25020000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	32054000	USD
CY2019Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	35979000	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24627000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	150008000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	146555000	USD
CY2019Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	55846000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	39198000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	205854000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	185753000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2018Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	54000	USD
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	53000	USD
CY2019Q3	us-gaap	Treasury Stock Value TreasuryStockValue	516950000	USD
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	489026000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	585476000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	533164000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-7794000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-6199000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1047573000	USD
	masi	Royaltyrevenueandother Royaltyrevenueandother	26696000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	931073000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1108359000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	969065000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1314213000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1154818000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	228916000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202068000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	688974000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	608461000	USD
CY2019Q3	masi	Royaltyrevenueandother Royaltyrevenueandother	95000	USD
CY2018Q3	masi	Royaltyrevenueandother Royaltyrevenueandother	8515000	USD
	masi	Royaltyrevenueandother Royaltyrevenueandother	1353000	USD
CY2019Q3	us-gaap	Revenues Revenues	229011000	USD
CY2018Q3	us-gaap	Revenues Revenues	210583000	USD
	us-gaap	Revenues Revenues	690327000	USD
	us-gaap	Revenues Revenues	635157000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	72743000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	69830000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	228078000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	208596000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	156268000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	140753000	USD
	us-gaap	Gross Profit GrossProfit	462249000	USD
	us-gaap	Gross Profit GrossProfit	426561000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80354000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71537000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	232718000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	212204000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24282000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20575000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69872000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60219000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	104636000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	92112000	USD
	us-gaap	Operating Expenses OperatingExpenses	302590000	USD
	us-gaap	Operating Expenses OperatingExpenses	272423000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	51632000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	48641000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	159659000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	154138000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2723000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1028000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10138000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4080000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	54355000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	49669000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	169797000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	158218000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5270000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7457000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26502000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11609000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	49085000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	57126000	USD
	us-gaap	Profit Loss ProfitLoss	143295000	USD
	us-gaap	Profit Loss ProfitLoss	146609000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.92
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.82
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.62
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53535000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52432000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53367000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52046000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57262000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56237000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57055000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55875000	shares
CY2019Q3	us-gaap	Profit Loss ProfitLoss	49085000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	57126000	USD
	us-gaap	Profit Loss ProfitLoss	143295000	USD
	us-gaap	Profit Loss ProfitLoss	146609000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1310000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	179000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1595000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2877000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	123000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6867000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	47775000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	57305000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	141700000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	143732000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	969065000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7317000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	49322000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	49322000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-577000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1005076000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5999000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11473000	USD
CY2019Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27854000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	44888000	USD
CY2019Q2	us-gaap	Profit Loss ProfitLoss	44888000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	292000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1039874000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9925000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10855000	USD
CY2019Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	70000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	49085000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	49085000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1310000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1108359000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	724025000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8880000	USD
CY2018Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	168000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5332000	USD
CY2018Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	16490000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	45630000	USD
CY2018Q1	us-gaap	Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple	-426000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-270000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	766513000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10891000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6720000	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	43853000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2786000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	825191000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22259000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15959000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19695000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-149000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29645000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-641000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	678000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-401000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-19000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6747000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7643000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	57126000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	179000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	912398000	USD
	us-gaap	Profit Loss ProfitLoss	143295000	USD
	us-gaap	Profit Loss ProfitLoss	146609000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17569000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21697000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-17384000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15221000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1069000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12060000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	15606000	USD
	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	-9396000	USD
	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-8901000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	10400000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	68000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-496000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1223000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4090000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-975000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1919000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	389000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5695000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3430000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	410000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6760000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3981000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1259000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6351000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	151416000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	176305000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	120000000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56064000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12299000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2968000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4718000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	4000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5189000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-453000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-184221000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20564000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22706000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42297000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	123000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	168000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	27924000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18478000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5341000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23651000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-983000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1230000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-39129000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	178162000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	552641000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315483000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	513512000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493645000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="line-height:120%;padding-top:17px;font-size:10pt;"><span style="font-weight:bold;">1. Description of the Company</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies and hospital automation solutions. The Company’s mission is to </span><span style="font-family:inherit;font-size:10pt;">improve patient outcomes and reduce the cost of care</span><span style="font-family:inherit;font-size:10pt;">. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company invented Masimo Signal Extraction Technology</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(SET</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), which provides the capabilities of </span><span>Measure-through Motion and Low Perfusion</span><span style="font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup> </span><span style="font-family:inherit;font-size:10pt;"> pulse oximetry to address the primary limitations of conventional pulse oximetry. Over the years, the Company’s product offerings have expanded significantly to also include rainbow</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Pulse CO-Oximetry, with its ability to monitor carboxyhemoglobin (SpCO</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), methemoglobin (SpMet</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), total hemoglobin concentration (SpHb</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), fractional arterial oxygen saturation (SpfO</span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">), Oxygen Content (SpOC</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">), Pleth Variability Index (PVi</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), rainbow</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Pleth Variability Index (RPVi</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">), respiration rate from the pleth (RRp</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">) and Oxygen Reserve Index (ORi</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">); as well as acoustic respiration monitoring (RRa</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), SedLine</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> brain function monitoring, NomoLine</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> capnography and gas monitoring and O3</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> regional oximetry. These technologies are based upon Masimo SET</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, rainbow</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and other proprietary algorithms and are incorporated into a variety of product platforms depending on customers’ specifications. The Company’s current technology offerings also include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span><span style="font-family:inherit;font-size:10pt;">, Masimo Patient SafetyNet Surveillance</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span><span style="font-family:inherit;font-size:10pt;">, Replica</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">, Iris</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, MyView</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, UniView</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;"> and Trace</span><span style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">™</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company’s technologies are supported by a substantial intellectual property portfolio that the Company has built through internal development and, to a lesser extent, acquisitions and license agreements.</span></div>
	us-gaap	Fiscal Period FiscalPeriod	<div style="line-height:120%;padding-top:17px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fiscal Periods</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 fiscal weeks while a 53 week fiscal year includes three 13 fiscal week quarters and one 14 fiscal week quarter. The Company’s last 53 week fiscal year was fiscal year 2014. Fiscal year </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is a 52 week fiscal year. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:17px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of total contract consideration and how such consideration should be allocated to each performance obligation within a contract, credit loss allowances on accounts and lease receivables, inventory reserves, warranty reserves, rebate accruals, valuation of the Company’s equity awards, goodwill valuation, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;padding-top:17px;text-align:left;padding-left:18px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including previously reported selling, general and administrative expenses that have been reclassified as research and development expenses within the condensed consolidated financial statements for the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 29, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div>
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	120000000.0	USD
	masi	Numberof Sourcesof Product Revenue NumberofSourcesofProductRevenue	4	segment
	masi	Royalty Revenue Numberof Days Royalty Revenueis Adjusted Subsequentto Quarter End RoyaltyRevenueNumberofDaysRoyaltyRevenueisAdjustedSubsequenttoQuarterEnd	P60D
CY2019Q3	masi	Royalty Royalty	0.0	USD
CY2018Q3	masi	Royalty Royalty	8100000	USD
	masi	Royalty Royalty	700000	USD
	masi	Royalty Royalty	25300000	USD
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1910000	USD
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1149000	USD
	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	1920000	USD
	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	943000	USD
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	1404000	USD
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	779000	USD
	us-gaap	Product Warranty Expense ProductWarrantyExpense	1276000	USD
	us-gaap	Product Warranty Expense ProductWarrantyExpense	974000	USD
CY2019Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3958000	USD
CY2018Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1897000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1100000	shares
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-6199000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-7794000	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	49085000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	57126000	USD
	us-gaap	Net Income Loss NetIncomeLoss	143295000	USD
	us-gaap	Net Income Loss NetIncomeLoss	146609000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53535000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52432000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53367000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52046000	shares
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.92
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.82
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53535000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52432000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53367000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52046000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3727000	shares
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3805000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3688000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3829000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57262000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56237000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57055000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55875000	shares
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.62
	us-gaap	Interest Paid Net InterestPaidNet	134000	USD
	us-gaap	Interest Paid Net InterestPaidNet	184000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	34123000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	29003000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	5076000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25965000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4170000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2023000	USD
	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	0	USD
	masi	Proceedsfromstockoptionsexercisedunsettledatperiodend Proceedsfromstockoptionsexercisedunsettledatperiodend	259000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	513360000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493488000	USD
CY2019Q3	us-gaap	Restricted Cash RestrictedCash	152000	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	157000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	513512000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493645000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Rou Assetsand Lease Liabilities CumulativeEffectonRetainedEarningsNetofTaxROUAssetsandLeaseLiabilities	22500000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Lease Receivable CumulativeEffectonRetainedEarningsNetofTaxLeaseReceivable	62000000.0	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Leased Equipment CumulativeEffectonRetainedEarningsNetofTaxLeasedEquipment	103500000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Deferred Tax Assets CumulativeEffectonRetainedEarningsNetofTaxDeferredTaxAssets	8600000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Deferred Tax Deferred Revenueand Contract Related Liabilities CumulativeEffectonRetainedEarningsNetofTaxDeferredTaxDeferredRevenueandContractRelatedLiabilities	9100000	USD
CY2018Q4	masi	Cumulative Effecton Retained Earnings Netof Tax Other Current Liabilities CumulativeEffectonRetainedEarningsNetofTaxOtherCurrentLiabilities	3000000.0	USD
	masi	Property Plantand Equipment Occupied Square Feet PropertyPlantandEquipmentOccupiedSquareFeet	16830	sqft
CY2019Q3	masi	Estimateof Annual Preventable Hospital Deaths Preventedby2020 EstimateofAnnualPreventableHospitalDeathsPreventedby2020	200000	death
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	53549000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	38955000	USD
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10185000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9036000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	45955000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	46741000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	109689000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	94732000	USD
CY2019Q3	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	19855000	USD
CY2018Q4	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	0	USD
CY2019Q3	us-gaap	Prepaid Taxes PrepaidTaxes	15013000	USD
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3071000	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10052000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10582000	USD
CY2019Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	7115000	USD
CY2018Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	6516000	USD
CY2019Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	2954000	USD
CY2018Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	3780000	USD
CY2019Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	5780000	USD
CY2018Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	5278000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	60769000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	29227000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	67669000	USD
CY2019Q3	masi	Salestypelease Allowancefor Credit Loss SalestypeleaseAllowanceforCreditLoss	372000	USD
CY2019Q3	us-gaap	Sales Type Lease Lease Receivable SalesTypeLeaseLeaseReceivable	67297000	USD
CY2019Q3	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	19855000	USD
CY2019Q3	us-gaap	Net Investment In Lease Noncurrent NetInvestmentInLeaseNoncurrent	47442000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	5183000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	18983000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	15009000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears	11891000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears	7928000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter	8675000	USD
CY2019Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	67669000	USD
CY2019Q3	masi	Prepaid Discount PrepaidDiscount	5872000	USD
CY2018Q4	masi	Prepaid Discount PrepaidDiscount	7036000	USD
CY2019Q3	us-gaap	Deferred Sales Commission DeferredSalesCommission	5121000	USD
CY2018Q4	us-gaap	Deferred Sales Commission DeferredSalesCommission	5085000	USD
CY2019Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2396000	USD
CY2018Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	5567000	USD
CY2019Q3	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	431000	USD
CY2018Q4	masi	Equipmentleasedtocustomers Equipmentleasedtocustomers	108417000	USD
CY2019Q3	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	13820000	USD
CY2018Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	126105000	USD
CY2019Q3	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	200000	USD
CY2018Q3	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	7400000	USD
	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	800000	USD
	masi	Deferred Costof Goods Sold Amortization DeferredCostofGoodsSoldAmortization	22200000	USD
CY2019Q3	masi	Deferred Costof Goods Sold Accumulated Amortization DeferredCostofGoodsSoldAccumulatedAmortization	1100000	USD
CY2018Q4	masi	Deferred Costof Goods Sold Accumulated Amortization DeferredCostofGoodsSoldAccumulatedAmortization	103100000	USD
CY2019Q3	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	600000	USD
CY2018Q3	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	500000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	1800000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	1300000	USD
CY2019Q3	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	500000	USD
	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	1500000	USD
	us-gaap	Amortization Of Deferred Sales Commissions AmortizationOfDeferredSalesCommissions	1600000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	4000000.0	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	319987000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	4800000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	263762000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	110529000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	97790000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	209458000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165972000	USD
	us-gaap	Depreciation Depreciation	14300000	USD
	us-gaap	Depreciation Depreciation	12100000	USD
CY2019Q3	masi	Properties Purchased PropertiesPurchased	2	Facilities
CY2019Q3	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	35600000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.037
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19892000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4680000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16451000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	21131000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1332000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5180000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3139000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2053000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1836000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11106000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24646000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3515000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6926000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4422000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2384000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1701000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1568000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	21131000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	9921000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	26922000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1717000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	5170000	USD
CY2019Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000	USD
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	52000	USD
	us-gaap	Sublease Income SubleaseIncome	156000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	1665000	USD
	us-gaap	Lease Cost LeaseCost	5026000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5200000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	56991000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	55158000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29559000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27234000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27432000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27924000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	4417000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4015000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3572000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2308000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1838000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	11282000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27432000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	23297000	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-651000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-649000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	21997000	USD
CY2018Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	4000000.0	USD
CY2018Q3	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2800000	USD
CY2018Q3	masi	Deferred Tax Adjustmentfrom Purchase Price Allocation DeferredTaxAdjustmentfromPurchasePriceAllocation	700000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19892000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Equity Method Investments EquityMethodInvestments	6287000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1200000	USD
CY2019Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3048000	USD
CY2018Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2881000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29378000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4232000	USD
CY2019Q3	us-gaap	Deferred Revenue DeferredRevenue	14861000	USD
CY2018Q4	us-gaap	Deferred Revenue DeferredRevenue	10883000	USD
CY2019Q3	masi	Accruedrebatesandallowances Accruedrebatesandallowances	6845000	USD
CY2018Q4	masi	Accruedrebatesandallowances Accruedrebatesandallowances	6282000	USD
CY2019Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	3509000	USD
CY2018Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	16194000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1979000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	432000	USD
CY2019Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	27194000	USD
CY2018Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	33791000	USD
CY2019Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2174000	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1737000	USD
CY2019Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25020000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	32054000	USD
CY2018Q4	us-gaap	Deferred Revenue DeferredRevenue	10883000	USD
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	9249000	USD
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	5271000	USD
CY2019Q3	us-gaap	Deferred Revenue DeferredRevenue	14861000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	204696000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	302540000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	143841000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	37259000	USD
CY2019Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	688336000	USD
CY2019Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	6488000	USD
CY2018Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	3071000	USD
CY2019Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	5712000	USD
CY2018Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	6465000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5387000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5038000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4680000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3958000	USD
CY2018Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1910000	USD
CY2019Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3452000	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4000000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	3277000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1481000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3025000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2662000	USD
CY2019Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	35979000	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24627000	USD
CY2019Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1700000	USD
CY2019Q3	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	21522000	USD
CY2018Q4	masi	Income Tax Payable Noncurrent IncomeTaxPayableNoncurrent	21522000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16451000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	12744000	USD
CY2018Q4	masi	Unrecognized Tax Benefits Liabilities Noncurrent UnrecognizedTaxBenefitsLiabilitiesNoncurrent	11717000	USD
CY2019Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2925000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2956000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2204000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3003000	USD
CY2019Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	55846000	USD
CY2018Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	39198000	USD
CY2019Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4800000	USD
CY2019Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1000	shares
CY2018Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	208000	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	196000	shares
CY2019Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	139.91
CY2018Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	134.05
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	84.14
CY2019Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	70000	USD
CY2018Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27924000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	16490000	USD
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10900000	USD
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7600000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	29600000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	19700000	USD
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10900000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2400000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5676000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	43.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	447000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	138.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	132000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	79.27
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	699000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	32.61
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5292000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	52.18
CY2019Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	15000000.0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3412000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	P3Y
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	44.14
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	37.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	31.21
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	500300000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	386600000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	33700000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	76100000	USD
CY2019Q3	us-gaap	Interest Income Other InterestIncomeOther	3664000	USD
CY2018Q3	us-gaap	Interest Income Other InterestIncomeOther	2326000	USD
	us-gaap	Interest Income Other InterestIncomeOther	10706000	USD
	us-gaap	Interest Income Other InterestIncomeOther	5247000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	82000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	7000	USD
	us-gaap	Interest Expense InterestExpense	243000	USD
	us-gaap	Interest Expense InterestExpense	694000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-856000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1311000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-315000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-764000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-291000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2723000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1028000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10138000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4080000	USD
CY2019Q3	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	7000000.0	USD
CY2018Q3	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	14600000	USD
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	13100000	USD
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	21700000	USD
CY2019Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16300000	USD
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2019Q3	us-gaap	Other Commitment OtherCommitment	2300000	USD
CY2018Q3	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.123
CY2018Q3	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.094
	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.132
	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.110
	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.124
	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.104
	masi	Supplemental Unemployment Benefits Severance Benefits Required Noticeof Resignation SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation	P6M
CY2019Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	90000000.0	USD
CY2019Q3	us-gaap	Cash Cash	633400000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	120000000.0	USD
CY2019Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	513400000	USD
CY2019Q3	us-gaap	Cash Cash	633400000	USD
CY2019Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3500000	USD
CY2019Q3	masi	Percentage Of Revenue One Customer PercentageOfRevenueOneCustomer	0.126
CY2019Q3	masi	Percentage Of Revenue Two Customer PercentageOfRevenueTwoCustomer	0.106
CY2019Q3	masi	Severance Plan Participation Agreements SeverancePlanParticipationAgreements	8	Agreement
CY2019Q3	masi	Concentration Risk Ar Customer ConcentrationRiskARCustomer	1	Customer
CY2019Q3	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	10500000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	228916000	USD
CY2019Q3	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202068000	USD
CY2018Q3	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	688974000	USD
	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	608461000	USD
	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1.000
CY2019Q3	us-gaap	Noncurrent Assets NoncurrentAssets	209889000	USD
CY2019Q3	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000
CY2018Q4	us-gaap	Noncurrent Assets NoncurrentAssets	274389000	USD
CY2018Q4	masi	Concentration Risk Longlived Asset Geographic Area Percentage ConcentrationRiskLonglivedAssetGeographicAreaPercentage	1.000

Files In Submission

Name	View Source	Status
0000937556-19-000179-index-headers.html	Edgar Link	pending
0000937556-19-000179-index.html	Edgar Link	pending
0000937556-19-000179.txt	Edgar Link	pending
0000937556-19-000179-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
masi-20190928.xsd	Edgar Link	pending
masi-20190928x10q.htm	Edgar Link	pending
masi-20190928x10qex311.htm	Edgar Link	pending
masi-20190928x10qex312.htm	Edgar Link	pending
masi-20190928x10qex321.htm	Edgar Link	pending
masi-20190928x10q_htm.xml	Edgar Link	completed
masi-20190928_cal.xml	Edgar Link	unprocessable
masi-20190928_def.xml	Edgar Link	unprocessable
masi-20190928_lab.xml	Edgar Link	unprocessable
masi-20190928_pre.xml	Edgar Link	unprocessable
masimologoq32019.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MASI
MASIMO CORP Stock $masi

2019 Q3 Form 10-Q Financial Statement

#000093755619000179 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI MASIMO CORP Stock $masi

2019 Q3 Form 10-Q Financial Statement

#000093755619000179 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MASI
MASIMO CORP Stock $masi